Cargando…

76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia

BACKGROUND: Systemic corticosteroids (steroids) have been empirically used in acute respiratory distress syndrome, an entity also present in coronavirus disease 19 (COVID-19). Early steroids administration could accelerate resolution of symptoms and reduce intensive care unit (ICU) stay in these pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Papamanoli, Aikaterini, Kalogeropoulos, Andreas, Fung, Jenny, Nakamura, Jacquelyn, Yoo, Jeanwoo, Grewal, Prabhjot, Karkala, Nikitha, Abata, Joshua, Tsui, Stella T, Coritsidis, Alexandra, Mojahedi, Azad, Jacob, Robin, Hotelling, Jessica, Dhaliwal, Simrat, Rawal, Sahil, Marcos, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778279/
http://dx.doi.org/10.1093/ofid/ofaa439.386
_version_ 1783631098333364224
author Papamanoli, Aikaterini
Kalogeropoulos, Andreas
Fung, Jenny
Nakamura, Jacquelyn
Yoo, Jeanwoo
Grewal, Prabhjot
Karkala, Nikitha
Abata, Joshua
Tsui, Stella T
Coritsidis, Alexandra
Mojahedi, Azad
Jacob, Robin
Hotelling, Jessica
Dhaliwal, Simrat
Rawal, Sahil
Marcos, Luis
author_facet Papamanoli, Aikaterini
Kalogeropoulos, Andreas
Fung, Jenny
Nakamura, Jacquelyn
Yoo, Jeanwoo
Grewal, Prabhjot
Karkala, Nikitha
Abata, Joshua
Tsui, Stella T
Coritsidis, Alexandra
Mojahedi, Azad
Jacob, Robin
Hotelling, Jessica
Dhaliwal, Simrat
Rawal, Sahil
Marcos, Luis
author_sort Papamanoli, Aikaterini
collection PubMed
description BACKGROUND: Systemic corticosteroids (steroids) have been empirically used in acute respiratory distress syndrome, an entity also present in coronavirus disease 19 (COVID-19). Early steroids administration could accelerate resolution of symptoms and reduce intensive care unit (ICU) stay in these patients, but practice varies widely as evidence is scant. METHODS: We reviewed the records of 498 adults admitted to Stony Brook University Hospital, NY, from 3/1 to 4/15, 2020 with COVID-19 requiring high-flow O2 (non-rebreather mask, Venturi mask with FiO2 >50%, or high-flow nasal cannula). We excluded those (N=29) who received mechanical ventilation (MV) or died within 24h of admission. We followed patients until death or discharge. We compared outcomes between patients who received early steroids (i.e. prior to MV) and those who did not. We used adjusted Cox models to evaluate the composite of death or need for MV. We also evaluated healthcare resources utilization. RESULTS: Of 469 patients, 175 (37.3%) received steroids while on high flow O2. Table 1 summarizes the baseline characteristics. Patients who received steroids were more likely to have asthma, had slightly longer duration of symptoms, lower O2 saturation, higher NT-proBNP and lower IL-6 levels at baseline. In total, 228 patients (48.6%) reached the composite endpoint (123 died and 105 received MV). By 7 days, 32.5% of patients who received steroids died or were intubated vs. 44.8% of those who did not (log-rank P=0.008), Figure 1. In models adjusted for race, age, sex, comorbidities, baseline O2 saturation and procalcitonin, steroids reduced risk for death or MV by 44% (hazard ratio [HR] 0.56; 95%CI 0.42–0.76; P< 0.001). The effect was time-dependent with initial HR 0.34 (95%CI 0.21–0.56; P< 0.001) and daily attenuation by 10.2% (95%CI 1.7%–19.4%; P=0.017). Mortality at 7 and 14 days did not differ between groups (8.1% vs. 8.3% and 19.1% vs. 21.0%, respectively, log-rank P=0.75). Among discharged patients, length of hospital stay was longer, but ICU stay was shorter with steroids, Table 2. Patient Characteristics According to Use of Early Steroids [Image: see text] [Image: see text] Healthcare Resources Utilization According to Use of Early Steroids Among Discharged Patients [Image: see text] CONCLUSION: Early administration of steroids reduced primarily the need for MV in our high-risk COVID-19 patients, with shorter ICU utilization, at the expense of longer hospital stay. Further studies are needed to optimize the use of steroids in these patients. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7778279
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77782792021-01-07 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia Papamanoli, Aikaterini Kalogeropoulos, Andreas Fung, Jenny Nakamura, Jacquelyn Yoo, Jeanwoo Grewal, Prabhjot Karkala, Nikitha Abata, Joshua Tsui, Stella T Coritsidis, Alexandra Mojahedi, Azad Jacob, Robin Hotelling, Jessica Dhaliwal, Simrat Rawal, Sahil Marcos, Luis Open Forum Infect Dis Poster Abstracts BACKGROUND: Systemic corticosteroids (steroids) have been empirically used in acute respiratory distress syndrome, an entity also present in coronavirus disease 19 (COVID-19). Early steroids administration could accelerate resolution of symptoms and reduce intensive care unit (ICU) stay in these patients, but practice varies widely as evidence is scant. METHODS: We reviewed the records of 498 adults admitted to Stony Brook University Hospital, NY, from 3/1 to 4/15, 2020 with COVID-19 requiring high-flow O2 (non-rebreather mask, Venturi mask with FiO2 >50%, or high-flow nasal cannula). We excluded those (N=29) who received mechanical ventilation (MV) or died within 24h of admission. We followed patients until death or discharge. We compared outcomes between patients who received early steroids (i.e. prior to MV) and those who did not. We used adjusted Cox models to evaluate the composite of death or need for MV. We also evaluated healthcare resources utilization. RESULTS: Of 469 patients, 175 (37.3%) received steroids while on high flow O2. Table 1 summarizes the baseline characteristics. Patients who received steroids were more likely to have asthma, had slightly longer duration of symptoms, lower O2 saturation, higher NT-proBNP and lower IL-6 levels at baseline. In total, 228 patients (48.6%) reached the composite endpoint (123 died and 105 received MV). By 7 days, 32.5% of patients who received steroids died or were intubated vs. 44.8% of those who did not (log-rank P=0.008), Figure 1. In models adjusted for race, age, sex, comorbidities, baseline O2 saturation and procalcitonin, steroids reduced risk for death or MV by 44% (hazard ratio [HR] 0.56; 95%CI 0.42–0.76; P< 0.001). The effect was time-dependent with initial HR 0.34 (95%CI 0.21–0.56; P< 0.001) and daily attenuation by 10.2% (95%CI 1.7%–19.4%; P=0.017). Mortality at 7 and 14 days did not differ between groups (8.1% vs. 8.3% and 19.1% vs. 21.0%, respectively, log-rank P=0.75). Among discharged patients, length of hospital stay was longer, but ICU stay was shorter with steroids, Table 2. Patient Characteristics According to Use of Early Steroids [Image: see text] [Image: see text] Healthcare Resources Utilization According to Use of Early Steroids Among Discharged Patients [Image: see text] CONCLUSION: Early administration of steroids reduced primarily the need for MV in our high-risk COVID-19 patients, with shorter ICU utilization, at the expense of longer hospital stay. Further studies are needed to optimize the use of steroids in these patients. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7778279/ http://dx.doi.org/10.1093/ofid/ofaa439.386 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Papamanoli, Aikaterini
Kalogeropoulos, Andreas
Fung, Jenny
Nakamura, Jacquelyn
Yoo, Jeanwoo
Grewal, Prabhjot
Karkala, Nikitha
Abata, Joshua
Tsui, Stella T
Coritsidis, Alexandra
Mojahedi, Azad
Jacob, Robin
Hotelling, Jessica
Dhaliwal, Simrat
Rawal, Sahil
Marcos, Luis
76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title_full 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title_fullStr 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title_full_unstemmed 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title_short 76. Effect of Early Administration of Systemic Corticosteroids on Outcomes in Patients with COVID-19 Pneumonia
title_sort 76. effect of early administration of systemic corticosteroids on outcomes in patients with covid-19 pneumonia
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778279/
http://dx.doi.org/10.1093/ofid/ofaa439.386
work_keys_str_mv AT papamanoliaikaterini 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT kalogeropoulosandreas 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT fungjenny 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT nakamurajacquelyn 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT yoojeanwoo 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT grewalprabhjot 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT karkalanikitha 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT abatajoshua 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT tsuistellat 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT coritsidisalexandra 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT mojahediazad 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT jacobrobin 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT hotellingjessica 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT dhaliwalsimrat 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT rawalsahil 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia
AT marcosluis 76effectofearlyadministrationofsystemiccorticosteroidsonoutcomesinpatientswithcovid19pneumonia